C
Chen Liu
Researcher at Rutgers University
Publications - 344
Citations - 21270
Chen Liu is an academic researcher from Rutgers University. The author has contributed to research in topics: Graft-versus-host disease & T cell. The author has an hindex of 72, co-authored 335 publications receiving 18611 citations. Previous affiliations of Chen Liu include University of Tennessee Health Science Center & University of Florida Health Science Center.
Papers
More filters
Journal ArticleDOI
Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL.
Alan M. Hanash,Lucy W. Kappel,Lucy W. Kappel,Nury L. Yim,Rebecca A. Nejat,Gabrielle L. Goldberg,Odette M. Smith,Uttam K. Rao,Lindsay Dykstra,Il-Kang Na,Il-Kang Na,Amanda M. Holland,Amanda M. Holland,Jarrod A Dudakov,Chen Liu,George F. Murphy,Warren J. Leonard,Glenn Heller,Marcel R.M. van den Brink,Marcel R.M. van den Brink +19 more
TL;DR: In a murine MHC-mismatched BM transplantation model, it is observed that IL-21 receptor knockout (IL-21R KO) donor T cells mediate decreased systemic and gastrointestinal GVHD in recipients of a transplant.
Journal ArticleDOI
Tumor Suppressor A20 Protects Against Cardiac Hypertrophy and Fibrosis by Blocking Transforming Growth Factor-β–Activated Kinase 1–Dependent Signaling
He Huang,Qi-Zhu Tang,Ai-Bing Wang,Manyin Chen,Ling Yan,Chen Liu,Hong Jiang,Qinglin Yang,Zhou-Yan Bian,Xue Bai,Lihua Zhu,Lang Wang,Hongliang Li +12 more
TL;DR: A20 improves cardiac functions and inhibits cardiac hypertrophy, inflammation, apoptosis, and fibrosis by blocking transforming growth factor-&bgr;–activated kinase 1–dependent signaling.
Journal ArticleDOI
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma
Xiangxuan Zhao,Changhai Tian,William Puszyk,Olorunseun O. Ogunwobi,Mengde Cao,Ton Wang,Roniel Cabrera,David R. Nelson,Chen Liu +8 more
TL;DR: It is shown that sorafenib triggers cell growth inhibition and apoptosis in HCC cells by directly targeting the mitochondria, and suggests that OPA1 is a novel therapeutic target in patients with HCC.
Journal ArticleDOI
Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects
Pavan Reddy,Takanori Teshima,Takanori Teshima,Gerhard C. Hildebrandt,Gerhard C. Hildebrandt,Debra L. Williams,Debra L. Williams,Chen Liu,Chen Liu,Kenneth R. Cooke,Kenneth R. Cooke,James L.M. Ferrara,James L.M. Ferrara +12 more
TL;DR: Pretreatment of donors with IL-18 prior to allogeneic BMT attenuates acute GVHD in a STAT6-dependent mechanism while preserving GVL effects, suggesting a critical role for STAT6 signaling in IL- 18's protective effect.
Journal ArticleDOI
Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation
Brian C. Betts,David Bastian,Supinya Iamsawat,Hung Nguyen,Jessica Heinrichs,Yongxia Wu,Anusara Daenthanasanmak,Anandharaman Veerapathran,Alison O'Mahony,Kelly Walton,Jordan Reff,Pedro Horna,Elizabeth M. Sagatys,Marie C. Lee,Jack W. Singer,Ying-Jun Chang,Chen Liu,Joseph Pidala,Claudio Anasetti,Xue-Zhong Yu +19 more
TL;DR: It is demonstrated that inhibition of Janus kinase 2 (JAK2) significantly decreases GVHD and maintains tumor killing by the donor T cells and pacritinib spares iTregs and polarizes Th2 responses as observed among JAK2−/− T cells.